Clinical trials
Adebrelimab (SHR-1316) clinical trials
Below are recruiting adebrelimab (shr-1316) clinical trials, each written for real people, not researchers. We’re tracking 11 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06879145RecruitingPhase 2/Phase 3
Study of SHR-A2102 and Adebrelimab for muscle-invasive bladder cancer
This trial tests a combination of two drugs, SHR-A2102 and Adebrelimab, for people with muscle-invasive bladder cancer that hasn't spread. The goal is to see if this treatment can help control the cancer.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06506292RecruitingPhase 2
Study of adebrelimab plus chemo before and after stomach cancer surgery
This trial tests combining adebrelimab (an immunotherapy) with chemotherapy (XELOX) before and after surgery for stomach cancer that hasn't spread. The goal is to see if this approach helps shrink tumors and improves outcomes.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT03736863RecruitingPhase 2
Testing combinations of medicines for advanced throat cancer
This trial tests a combination of medicines to treat advanced esophageal squamous cell carcinoma (throat/esophagus cancer) that cannot be removed by surgery and has spread or come back. It is for people whose first treatment (chemotherapy or immunotherapy) did not work well or was not tolerated.
Zhengzhou, HenanAges 18–75 - NCT06454448RecruitingPhase 1/Phase 2
Adebrelimab plus chemotherapy for advanced pancreatic cancer
This trial tests a combination of a targeted immune therapy (Adebrelimab) with three chemotherapy drugs for people with metastatic pancreatic cancer who haven't had any treatment yet. The goal is to see if this combination can shrink tumors and help people live longer.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06589778RecruitingPhase 1/Phase 2
Study of three drugs for advanced lung cancer
This trial tests a combination of three drugs (SHR-A2102, Adebrelimab, and SHR-8068) for people with advanced non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink or slow the growth of the cancer.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06607276RecruitingPhase 2
Adjuvant adebrelimab and capecitabine for high-risk bile duct cancer
This trial is for people with bile duct cancer who have had surgery to remove all visible cancer but are at high risk of it coming back. It tests whether adding two medications — adebrelimab (an immunotherapy) and capecitabine (a chemotherapy pill) — after surgery can help prevent the cancer from returning.
Nanjing, JiangsuAges 18–75 - NCT06869213RecruitingPhase 2
Adebrelimab plus chemo before and after surgery for esophageal cancer
This trial tests a combination of the immunotherapy drug adebrelimab (SHR-1316) and chemotherapy given before and after surgery for locally advanced esophageal squamous cell carcinoma that can be removed. The goal is to see if this approach helps shrink the tumor and improves outcomes.
BeijingAges 18–75 - NCT07168200RecruitingPhase 3
Study of Adebrelimab with Chemoradiation for Advanced Cervical Cancer
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemoradiation helps treat locally advanced cervical cancer better than chemoradiation alone.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06222879RecruitingPhase 1/Phase 2
New drug combinations for advanced breast cancer
This trial tests a combination of new drugs (HRS-8080, SHR-A2009, or others) for people with advanced breast cancer that has stopped responding to previous treatments. The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
Changsha, HunanAges 18–75 - NCT06417554RecruitingPhase 1/Phase 2
Study of SHR-A2102 for advanced solid tumors
This trial is testing a new drug, SHR-A2102, either alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–80 - NCT06474468RecruitingPhase 1/Phase 2
Study of a new drug combo for advanced esophageal cancer
This trial tests a combination of two investigational drugs for people with advanced or metastatic esophageal squamous cell carcinoma. The goal is to see if the combination can shrink tumors or slow cancer growth.
Jinan, ShandongAges 18–70
Hear when a new Adebrelimab (SHR-1316) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for adebrelimab (shr-1316)?
- Yes. Clin2 currently lists 11 recruiting adebrelimab (shr-1316) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a adebrelimab (shr-1316) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a adebrelimab (shr-1316) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.